PMID- 30008842
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 16
IP  - 2
DP  - 2018 Aug
TI  - Serum long noncoding RNA LRB1 as a potential biomarker for predicting the 
      diagnosis and prognosis of human hepatocellular carcinoma.
PG  - 1593-1601
LID - 10.3892/ol.2018.8825 [doi]
AB  - Hepatocellular carcinoma (HCC) is a type of malignant tumor with a high mortality 
      rate. Long non-coding RNAs (lncRNAs) serve important roles in cellular processes 
      and gene regulation. Identifying novel prognostic biomarkers is important for the 
      monitoring and treatment of HCC. However, only a limited number of biomarkers 
      with high sensitivity and specificity have been determined and are used in 
      clinical practice. The aim of the present study was to investigate the use of 
      serum lncRNA uc007biz.1 (LRB1) expression levels as a novel non-invasive 
      biomarker for the monitoring and diagnosis of HCC. The expression levels of LRB1 
      were detected in 326 patients with HCC and 73 healthy volunteers by using lncRNA 
      expression microarrays and reverse transcription quantitative polymerase chain 
      reaction analysis, and the associations between LRB1 expression and clinical 
      parameters were analyzed. The results indicated that the serum LRB1 levels in 
      patients with HCC were significantly increased compared with healthy volunteers. 
      The serum LRB1 levels were positively associated with alpha-fetoprotein (AFP) 
      expression, large tumor sizes, tumor stage (tumor-node metastasis or Barcelona 
      Clinic Liver Cancer stage) and venous invasion, and were negatively associated 
      with overall survival. Additionally, the use of a combination of LRB1, AFP and 
      des-gamma-carboxy prothrombin (DCP) markers for the diagnosis of HCC, the diagnostic 
      accuracy was increased compared with using LRB1 alone. LRB1 may act as an 
      important regulator in the progression of HCC, and LRB1 may be considered as a 
      novel biomarker for diagnosis and prediction of prognosis of HCC, additionally 
      complementing the accuracy of AFP and DCP.
FAU - Wang, Zhi-Feng
AU  - Wang ZF
AD  - Department of Gastroenterology, The First Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050030, P.R. China.
FAU - Hu, Rui
AU  - Hu R
AD  - Department of Gastroenterology, The First Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050030, P.R. China.
FAU - Pang, Jian-Min
AU  - Pang JM
AD  - Department of Gastroenterology, The First Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050030, P.R. China.
FAU - Zhang, Gui-Zhen
AU  - Zhang GZ
AD  - Department of Gastroenterology, The First Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050030, P.R. China.
FAU - Yan, Wei
AU  - Yan W
AD  - Department of Gastroenterology, The First Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050030, P.R. China.
FAU - Li, Zeng-Ning
AU  - Li ZN
AD  - Department of Gastroenterology, The First Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050030, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20180530
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC6036462
OTO - NOTNLM
OT  - des-gamma-carboxy prothrombin
OT  - hepatocellular carcinoma
OT  - long non-coding RNA uc007biz.1
OT  - alpha-fetoprotein
EDAT- 2018/07/17 06:00
MHDA- 2018/07/17 06:01
PMCR- 2018/05/30
CRDT- 2018/07/17 06:00
PHST- 2016/11/08 00:00 [received]
PHST- 2017/11/20 00:00 [accepted]
PHST- 2018/07/17 06:00 [entrez]
PHST- 2018/07/17 06:00 [pubmed]
PHST- 2018/07/17 06:01 [medline]
PHST- 2018/05/30 00:00 [pmc-release]
AID - OL-0-0-8825 [pii]
AID - 10.3892/ol.2018.8825 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Aug;16(2):1593-1601. doi: 10.3892/ol.2018.8825. Epub 2018 May 
      30.